Roche’s $4.3 billion purchase of Spark Therapeutics approved by US antitrust
17.12.2019 - Petr Mazaylo
Roche’s $4.3 billion purchase of Spark Therapeutics approved by US antitrust

Swiss drugmaker Roche has been approved by US antitrust to buy gene therapy specialist Spark Therapeutics in a $4.3 billion deal. This move allows Roche to advance its push in treating rare diseases like Hemophilia A.

The Federal Trade Commission stated that it has approved the deal, without requiring Roche asset sales that will assure that the merger complies with antitrust law.

In a statement, the FTC said that the evidence “did not indicate that Roche would have the incentive to delay or terminate Spark’s developmental effort for its Hemophilia A gene therapy, or that the acquisition would affect Roche’s incentives regarding (its hemophilia treatment drug) Hemlibra.”

The approval of US antitrust was the last leg in the merger of the two companies.

When the merger deal was initially announced, an agreement stating that Roche was going to pay a big premium for Spark, the amount of which was double of the company’s closing price on Feb. 22.

Roche buying Spark is a measure done by the company to gain footing in gene therapy and to make addition to its hemophilia A products. Its anti-hemophilia A drug, Hemlibra, is about to exceed $1 billion in sales this year.

People who have hemophilia suffer with a deficiency in protein that aids in blood-clotting, risking them with serious health issues such as internal bleeding, joint damage, or death.

Traditionally, hemophilia has been the most expensive and lucrative treatment areas, with clotting factors running millions of dollars annually.

Risk disclaimer "Market Solutions Ltd – Suite 305 Griffith Corporate Centre P.O. Box 1510 Beachmont, Kingstown, St Vincent and the Grenadines is a financial services institution outside the European Union Area, which is subject to the supervision of the IFMRRC Certificate 0395 AA V0128 Trading in Forex/ CFDs and Other Derivatives is highly speculative and carries a high level of risk. It is possible to lose all your capital. 70% of trading deals can be unprofitable. These products may not be suitable for everyone and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. This Website may contain information in particular regarding financial services and products that could be regarded b a E.U. supervisory authority as an offer of financial services targeted in Europe. ESMA intervention measures do not apply to customers of Market solutions Ltd and it is your responsibility to choose a company which is most suitable for your trading needs. By clicking continue you confirm that you have read, understood and agree to the risk disclosures, terms of service, cash policies, privacy policies and this notice and that you are visiting this website on your own initiative, without any encouragement whatsoever from Umarkets.com or Market Solutions limited." Cookies notification: “We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we assume that you are happy with it. Continue
×

Help with deposit?